Tags

Type your tag names separated by a space and hit enter

The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario.
Indian J Ophthalmol. 2018 06; 66(6):831-836.IJ

Abstract

Purpose

This study evaluated the effect of intravitreal dexamethasone implant (IDI; Ozurdex) injection for treating macular edema in patients with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

Methods

This prospective study included 40 eyes of 40 patients with nonischemic BRVO and 31 eyes of 31 patients with nonischemic CRVO who received IDI injection as the first-line treatment for macular edema. The best-corrected visual acuity (BCVA) value before and after the treatment; intraocular pressure; optic coherence tomography findings; and all ocular examination findings, including central foveal thickness (CFT) measurement and fluorescein angiography findings, were evaluated for each patient.

Results

After the IDI injection, BCVA value increased (P < 0.001) and CFT value decreased (P < 0.001) in both groups. The recurrence rates of CFT elevation after the first and the second Ozurdex injections were 65.0% and 65.3%, respectively, in patients with BRVO and 70.9% and 68.1%, respectively, in patients with CRVO. A statistically significant correlation was observed between preinjection CFT value and postinjection recurrence of CFT elevation (P = 0.017).

Conclusion

Treatment with the IDI injections resulted in significant short-term improvement in CFT and BCVA values in patients with clinically significant RVO-related macular edema. Moreover, we observed that high preinjection CFT value was associated with a risk of postinjection recurrence of CFT elevation.

Authors+Show Affiliations

Department of Ophthalmology, Sorgun State Hospital, Yozgat, Turkey.Department of Ophthalmology, Ulucanlar Eye Education and Research Hospital, Ankara, Turkey.Department of Ophthalmology, Dr. Sami Ulus Maternity and Children's Health and Diseases Training and Research Hospital, Ankara, Turkey.Department of Ophthalmology, Ulucanlar Eye Education and Research Hospital, Ankara, Turkey.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29785994

Citation

Simsek, Mert, et al. "The Efficacy of Intravitreal Dexamethasone Implant as the First-line Treatment for Retinal Vein Occlusion-related Macular Edema in a Real-life Scenario." Indian Journal of Ophthalmology, vol. 66, no. 6, 2018, pp. 831-836.
Simsek M, Citirik M, Ozates S, et al. The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario. Indian J Ophthalmol. 2018;66(6):831-836.
Simsek, M., Citirik, M., Ozates, S., & Ozkoyuncu, D. (2018). The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario. Indian Journal of Ophthalmology, 66(6), 831-836. https://doi.org/10.4103/ijo.IJO_1259_17
Simsek M, et al. The Efficacy of Intravitreal Dexamethasone Implant as the First-line Treatment for Retinal Vein Occlusion-related Macular Edema in a Real-life Scenario. Indian J Ophthalmol. 2018;66(6):831-836. PubMed PMID: 29785994.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario. AU - Simsek,Mert, AU - Citirik,Mehmet, AU - Ozates,Serdar, AU - Ozkoyuncu,Dilara, PY - 2018/5/23/entrez PY - 2018/5/23/pubmed PY - 2018/7/18/medline KW - Branch retinal vein occlusion KW - Ozurdex implant KW - central retinal vein occlusion KW - dexamethasone implant KW - macular edema SP - 831 EP - 836 JF - Indian journal of ophthalmology JO - Indian J Ophthalmol VL - 66 IS - 6 N2 - Purpose: This study evaluated the effect of intravitreal dexamethasone implant (IDI; Ozurdex) injection for treating macular edema in patients with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Methods: This prospective study included 40 eyes of 40 patients with nonischemic BRVO and 31 eyes of 31 patients with nonischemic CRVO who received IDI injection as the first-line treatment for macular edema. The best-corrected visual acuity (BCVA) value before and after the treatment; intraocular pressure; optic coherence tomography findings; and all ocular examination findings, including central foveal thickness (CFT) measurement and fluorescein angiography findings, were evaluated for each patient. Results: After the IDI injection, BCVA value increased (P < 0.001) and CFT value decreased (P < 0.001) in both groups. The recurrence rates of CFT elevation after the first and the second Ozurdex injections were 65.0% and 65.3%, respectively, in patients with BRVO and 70.9% and 68.1%, respectively, in patients with CRVO. A statistically significant correlation was observed between preinjection CFT value and postinjection recurrence of CFT elevation (P = 0.017). Conclusion: Treatment with the IDI injections resulted in significant short-term improvement in CFT and BCVA values in patients with clinically significant RVO-related macular edema. Moreover, we observed that high preinjection CFT value was associated with a risk of postinjection recurrence of CFT elevation. SN - 1998-3689 UR - https://www.unboundmedicine.com/medline/citation/29785994/The_efficacy_of_intravitreal_dexamethasone_implant_as_the_first_line_treatment_for_retinal_vein_occlusion_related_macular_edema_in_a_real_life_scenario_ L2 - http://www.ijo.in/article.asp?issn=0301-4738;year=2018;volume=66;issue=6;spage=831;epage=836;aulast=Simsek DB - PRIME DP - Unbound Medicine ER -